Myxedema Coma Diagnostic Score
Evidence to Action: Official Journal of MDCalc · 2025
DOI: 10.65357/001c.153938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence to Action: Official Journal of MDCalc, 2025. Verfasst von Michelle D. Lundholm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
The myxedema coma diagnostic score integrates clinical and laboratory parameters to assist in identifying patients affected by this rare, life-threatening manifestation of severe hypothyroidism. Derived and validated retrospectively from institutional and literature cohorts, the score demonstrated high sensitivity (100%) and moderate specificity (85.7%) for diagnosing myxedema coma with a cutoff ≥60. It is a practical diagnostic tool, but the score remains limited by small sample sizes and retrospective design, underscoring the need for further validation and cautious clinical application alongside endocrinology consultation.
Zitieren
APA
Lundholm, M. D. (2025). Myxedema Coma Diagnostic Score. Evidence to Action: Official Journal of MDCalc. https://doi.org/10.65357/001c.153938
Vancouver
Lundholm MD. Myxedema Coma Diagnostic Score. Evidence to Action: Official Journal of MDCalc. 2025. doi:10.65357/001c.153938
BibTeX
@article{Lundholm2025,
author = {Lundholm, Michelle D.},
title = {Myxedema Coma Diagnostic Score},
journal = {Evidence to Action: Official Journal of MDCalc},
year = {2025},
doi = {10.65357/001c.153938}
}
EUVIMED